Abstract Number: 2138 • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy Results of a Phase 2, Double-Blind, Placebo-Controlled Clinical Study of Duvelisib with Background Methotrexate (MTX) in Adults with Moderate-to-Severe Rheumatoid Arthritis (RA)
Background/Purpose: Duvelisib is a potent, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ,γ being developed for hematologic malignancies, and was also explored in early phase studies in…Abstract Number: 2493 • 2015 ACR/ARHP Annual Meeting
Improvement of Disease Activity and Quality of Care in a Cohort of Rheumatoid Arthritis Patients Treated with Conventional Dmard Therapy Under Treat to Target Recommendations and a Model of Patient-Centered Care
Background/Purpose: Treat to Target (T2T) strategy becomes from the need to develop therapeutic targets and tools to achieve defined outcomes in rheumatoid arthritis (RA). Moreover,…Abstract Number: 2408 • 2014 ACR/ARHP Annual Meeting
Frequency of Rheumatoid Arthritis Flares in Clinical Practice: Analysis of a Monocentric Cohort of Patients in Stable Remission or Low Disease Activity
Background/Purpose Rheumatoid arthritis (RA) flares are predictive of structural damage even in case of stable disease course. No definition for flare has been validated to…Abstract Number: 2409 • 2014 ACR/ARHP Annual Meeting
Omega-3 Fatty Acids and Mediterranean Diet As Complimentary Therapies for Rheumatoid Arthritis
Background/Purpose Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting the synovial joints, often with a progressive and destructive course, leading to disability. Nowadays, there…Abstract Number: 1972 • 2014 ACR/ARHP Annual Meeting
Analysis of Anakinra in Primary Human Cell Systems Reveals an in Vitro Signature for Skin-Related Side Effects
Background/Purpose The therapeutic options for treatment of rheumatic diseases have grown and now include a variety of inflammatory pathway inhibitors, with diverse mechanisms, but having…Abstract Number: 1529 • 2014 ACR/ARHP Annual Meeting
Evaluation of the Pharmacokinetics and Safety of the Interactions Between the Anti-Interleukin-6 Monoclonal Antibody Sirukumab and Cytochrome P450 Activities in Patients with Rheumatoid Arthritis
Background/Purpose: Interleukin 6 (IL-6) reduces the expression of cytochrome P450 (CYP) enzymes. The goal of the study was to evaluate: 1) the effect of sirukumab…Abstract Number: 1512 • 2014 ACR/ARHP Annual Meeting
Therapeutic Efficacy of a Novel Oral Small Molecule Macrophage Migration Inhibitory Factor [MIF] Inhibitor: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis
Background/Purpose: Macrophage migration inhibitory factor [MIF] is a cytokine secreted by activated T cells and macrophages that plays an important role in RA and autoimmune…Abstract Number: 1510 • 2014 ACR/ARHP Annual Meeting
Blockade of TLR5 Ligation Is a Novel Strategy for RA Therapy
Background/Purpose: TLR5 expression is highly elevated in RA and CIA lining and sublining macrophages and endothelial cells compared to non-arthritic controls. Additionally, expression of TLR5…Abstract Number: 2815 • 2014 ACR/ARHP Annual Meeting
Better Functional Ability with Less Biologicals 2 years after Induction with Combination DMARD Therapy versus methotrexate Monotherapy
Background/Purpose: To assess differences in frequency of biological therapy use and functional ability in early RA patients two years after starting induction therapy according to…Abstract Number: 1486 • 2014 ACR/ARHP Annual Meeting
Rapid Onset of Clinical Benefit Is Associated with a Reduction in Validated Biomarkers of Disease in Patients with Rheumatoid Arthritis Treated with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá
Background/Purpose Macrophages are pivotal to rheumatoid pathogenesis and their inflammatory products drive many of the signs and symptoms of disease. Mavrilimumab inhibits macrophage activation and…Abstract Number: 2825 • 2014 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Phase 3 Equivalence Trial Comparing the Etanercept Biosimilar, HD203, with Etanercept (Enbrel®), in Combination with Methotrexate (MTX) in Patients with Rheumatoid Arthritis (RA)
Background/Purpose Etanercept is a recombinant fusion protein that blocks TNF activity. HD203 is a biosimilar of etanercept. In a double-blind, randomized study in healthy volunteers,…Abstract Number: 1493 • 2014 ACR/ARHP Annual Meeting
A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results
Background/Purpose Activation of CSF1R via IL34 or CSF1 results in activation, differentiation, and survival of monocytes, macrophages and osteoclasts. CSF1R activation produces inflammatory cytokines responsible…Abstract Number: 2826 • 2014 ACR/ARHP Annual Meeting
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Not on Concomitant Methotrexate
Background/Purpose ASP015K is a novel oral Janus kinase (JAK) inhibitor in development for the treatment of rheumatoid arthritis (RA). ASP015K inhibits JAK 1/3 with relative…Abstract Number: 1356 • 2014 ACR/ARHP Annual Meeting
Collaboration Between a Third Party Payer and Community Rheumatologists to Create a Clinical Pathway for the Treatment of Rheumatoid Arthritis to Assure Proper Use of Biologics and Quality of Care
Background/Purpose Use of biologic agents for the treatment of rheumatoid arthritis continues to grow rapidly, with the cost of these agents putting a significant strain…Abstract Number: 2501 • 2014 ACR/ARHP Annual Meeting
Indirect Comparison of Tocilizumab and Tofacitinib in Patients with Rheumatoid Arthritis
Background/Purpose: Tocilizumab (TCZ) is a recombinant, humanized, monoclonal antibody directed against the cytokine interleukin-6 receptor, and tofacitinib (Tofa) is an oral, synthetic, disease-modifying antirheumatic drug…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 22
- Next Page »